pyrroles has been researched along with Parkinson Disease in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasantabar, V; Lakouraj, MM; Rezaei, M | 1 |
| Collins, LM; Foley, T; Goulding, SR; Mazzocchi, M; Morales-Prieto, N; O'Keeffe, GW; Sullivan, AM | 1 |
| Baptista, MAS; Barrett, T; Bhargava, S; Bryce, DK; Ellis, JM; Estrada, AA; Fell, MJ; Fiske, BK; Fuji, RN; Galatsis, P; Henry, AG; Hill, S; Hirst, W; Houle, C; Kennedy, ME; Liu, X; Maddess, ML; Markgraf, C; Mei, H; Meier, WA; Merchant, K; Needle, E; Ploch, S; Royer, C; Rudolph, K; Sharma, AK; Sherer, TB; Stepan, A; Steyn, S; Trost, C; Wang, X; Yin, Z; Yu, H | 1 |
| Henderson, MX; Lee, VMY; Peng, C; Trojanowski, JQ | 1 |
| Berger, Z; Chen, Y; Coffman, KJ; Galatsis, P; Hayward, MM; Henderson, JL; Hirst, WD; Houle, C; Jasti, J; Kormos, BL; Kurumbail, RG; Needle, E; Noell, GS; Steyn, SJ; Verhoest, PR; Wager, TT | 1 |
| Abdelmotilib, HA; Chen, Y; Daher, JP; Fraser, KB; Galatsis, P; Hirst, WD; Hu, X; Moehle, MS; Needle, E; Steyn, SJ; Volpicelli-Daley, LA; West, AB | 1 |
| Amini, N; Budd, S; Cselényi, Z; Farde, L; Halldin, C; Helin, S; Johnström, P; Jucaite, A; Kirjavainen, A; Kugler, AR; Minkwitz, M; Posener, JA; Rinne, JO; Svenningsson, P; Varnäs, K; Varrone, A | 1 |
| Jimenez-Del-Rio, M; Mendivil-Perez, M; Velez-Pardo, C | 1 |
| Alessi, DR; Deak, M; Dzamko, N; Hentati, F; Nichols, RJ; Prescott, AR; Reith, AD | 1 |
| Aman, A; Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB | 1 |
| BLOCKUS, LE; EVERETT, GM; SHEPPERD, IM | 1 |
| Kazis, LE; Lee, A; Lee, TA; Li, NC; Wang, SW; Wolozin, B | 1 |
| Brotchie, JM; Crossman, AR; Duty, S; Hille, CJ; Maneuf, YP | 1 |
| Castellani, R; Perry, G; Richey, PL; Smith, MA | 1 |
| Gorkin, VZ | 1 |
1 review(s) available for pyrroles and Parkinson Disease
| Article | Year |
|---|---|
[New data on monoamine oxidase inhibitors].
Topics: Acridines; Animals; Brain; Cytoplasm; Hydrazines; Iproniazid; Isoquinolines; Liver; Membranes; Mitochondria; Monoamine Oxidase Inhibitors; Oxadiazoles; Pargyline; Parkinson Disease; Pyridines; Pyrroles; Radiation Injuries; Rats; Tranylcypromine; Vitamin D | 1971 |
1 trial(s) available for pyrroles and Parkinson Disease
| Article | Year |
|---|---|
Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease.
Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Fluorine Radioisotopes; Follow-Up Studies; Humans; Male; Microglia; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Positron-Emission Tomography; Protein Binding; Pyrimidines; Pyrimidinones; Pyrroles; Receptors, GABA; Severity of Illness Index | 2015 |
13 other study(ies) available for pyrroles and Parkinson Disease
| Article | Year |
|---|---|
Synthesis, characterization and in-vitro prolonged release of L-DOPA using a novel amphiphilic hydrogel based on sodium alginate-polypyrrole.
Topics: Administration, Oral; Alginates; Antioxidants; Antiparkinson Agents; Drug Liberation; Fibroblasts; Humans; Hydrogels; Levodopa; Parkinson Disease; Polymers; Pyrroles | 2021 |
Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Histone Deacetylase Inhibitors; Histone Deacetylases; Hydroxamic Acids; Neurodegenerative Diseases; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Pyrroles; Rats; Substantia Nigra | 2022 |
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits.
Topics: Animals; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Lung; Morpholines; Mutation; Parkinson Disease; Primates; Pyrimidines; Pyrroles | 2020 |
LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
Topics: alpha-Synuclein; Animals; Animals, Newborn; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Embryo, Mammalian; Enzyme Inhibitors; Gene Expression Regulation; Hippocampus; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mesencephalon; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Nerve Tissue Proteins; Neurons; Organ Culture Techniques; Parkinson Disease; Pyrimidines; Pyrroles; Tyrosine 3-Monooxygenase | 2018 |
Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
Topics: Amino Acid Sequence; Animals; Area Under Curve; Brain; Crystallography, X-Ray; Drug Discovery; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice, Inbred C57BL; Mice, Transgenic; Models, Molecular; Molecular Sequence Data; Molecular Structure; Mutation, Missense; Nitriles; Parkinson Disease; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Proteome; Pyrimidines; Pyrroles; Rats | 2015 |
Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Dependovirus; Disease Models, Animal; Female; Gene Expression Regulation; Genetic Vectors; Humans; Injections, Intraventricular; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Parkinson Disease; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction; Substantia Nigra | 2015 |
Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.
Topics: Cell Death; Cell Differentiation; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mitochondria; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Phosphorylation; Protein Serine-Threonine Kinases; Pyrimidines; Pyrroles; Reactive Oxygen Species | 2016 |
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 14-3-3 Proteins; Amino Acid Sequence; Animals; Blotting, Western; Cell Line; Cells, Cultured; Cytoplasm; Dose-Response Relationship, Drug; Green Fluorescent Proteins; Humans; Inclusion Bodies; Indoles; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice; Microscopy, Fluorescence; Middle Aged; Mutation; Parkinson Disease; Phosphorylation; Protein Binding; Protein Serine-Threonine Kinases; Pyrroles; Serine; Sunitinib; Swiss 3T3 Cells | 2010 |
L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Drug Interactions; Dyskinesias; Female; Levodopa; Macaca; Male; Motor Activity; Parkinson Disease; Pyridines; Pyrroles; Receptors, Dopamine D4 | 2012 |
Tremor induced by tremorine and its antagonism by anti-Parkinson drugs.
Topics: Antiparkinson Agents; Humans; Parkinson Disease; Pyrroles; Tremor; Tremorine | 1956 |
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Databases as Topic; Dementia; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Parkinson Disease; Proportional Hazards Models; Pyrroles; Simvastatin; United States; Veterans | 2007 |
Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Benzopyrans; Cromakalim; Diazoxide; Disease Models, Animal; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Globus Pallidus; Ion Channel Gating; Locomotion; Male; Parkinson Disease; Potassium Channels; Pyrroles; Rats; Rats, Sprague-Dawley; Reserpine; Time Factors | 1996 |
Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease.
Topics: Aged; Aged, 80 and over; Arginine; Cerebral Cortex; Cross-Linking Reagents; Glycation End Products, Advanced; Glycosylation; Heme Oxygenase (Decyclizing); Humans; Immunohistochemistry; Locus Coeruleus; Lysine; Microscopy, Immunoelectron; Middle Aged; Neurons; Norleucine; Oxidative Stress; Parkinson Disease; Pyrroles; Substantia Nigra | 1996 |